文献速递外周动脉疾病

肝细胞生长因子对下肢外周动脉疾病步行能力的作用

Hepatocyte growth factor for walking performance in peripheral artery disease.
PubMed 文献 · J Vasc Surg · 2025-01-06

这项双盲初步临床试验将39例外周动脉疾病患者随机分配至腓肠肌注射VM202 4 mg或安慰剂,每14天一次共四次。主要结局6个月6分钟步行距离未改善(-13.5 m;90%CI,-38.5至+∞)。次要结局显示3个月跑步机最大步行时间改善(+2.38分钟;90%CI,+1.08至+∞;P=.014),事后分析提示合并糖尿病者可能获益。

要点

  • VM202未改善外周动脉疾病患者6个月6分钟步行距离。
  • 3个月跑步机最大步行时间较安慰剂改善2.38分钟(90%CI,1.08至+∞;P=.014)。
  • 事后分析提示合并糖尿病者6个月6分钟步行可能获益(交互P=.079)。

核心结论

  • 这些数据不支持腓肠肌注射VM202改善外周动脉疾病患者的6分钟步行。
  • 次要结局提示VM202对骨骼肌指标和跑步机步行可能有潜在获益,事后分析提示合并糖尿病的患者可能获益。

研究设计与样本

  • 双盲临床试验,39例外周动脉疾病患者随机接受腓肠肌注射VM202 4 mg或安慰剂,每14天一次共四次治疗。

主要发现

  • 校正年龄、种族、吸烟和基线表现后,VM202与安慰剂相比未改善6个月随访时的6分钟步行(-13.5 m;90%CI,-38.5至+∞)。
  • 3个月随访时,VM202与安慰剂相比改善跑步机最大步行时间(+2.38分钟;90%CI,+1.08至+∞;P=.014)并增加腓肠肌中央核丰度(+5.86;90%CI,+0.37至+∞;P=.088)。
  • VM202与安慰剂相比未显著改善无痛步行距离(差值+0.30分钟;90%CI,-1.10至+∞;P=.39)、小腿肌肉灌注(差值+1.80 mL/min每100 g组织;90%CI,-3.80至+∞;P=.33)或步行障碍问卷距离评分(差值+2.02;90%CI,-8.11至+∞;P=.40)。
  • 事后分析中,VM202与安慰剂相比在合并糖尿病的外周动脉疾病患者6个月随访时显著改善6分钟步行(+34.19;90%CI,4.04至+∞;P=.075),但在无糖尿病患者中无效果(交互P=.079)。

关键数值与推荐

  • 本初步试验预设统计学显著性为单侧P值小于.10。
  • 主要结局为6个月6分钟步行距离变化;次要结局包括3个月跑步机步行时间和腓肠肌活检指标变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: VM202 is a plasmid encoding two isoforms of hepatocyte growth factor. In preclinical studies, hepatocyte growth factor stimulated angiogenesis and muscle regeneration. This preliminary clinical trial tested the hypothesis that VM202 injections in gastrocnemius muscle would improve walking performance in people with mild to moderate and symptomatic lower extremity peripheral artery disease (PAD). METHODS: In a double-blind clinical trial, patients with PAD were randomized to gastrocnemius muscle injections of either 4 mg of VM202 or placebo every 14 days for four treatments. The primary outcome was 6-month change in 6-minute walk distance. Secondary outcomes included 3-month change in treadmill walking time and gastrocnemius muscle biopsy measures. In this preliminary trial, statistical significance was prespecified as a one-sided P value of less than .10. RESULTS: Thirty-nine participants with PAD (64.1% Black, 28.2% female) were randomized. Adjusting for age, race, smoking, and baseline performance, VM202 did not improve 6-minute walk at 6-month follow-up, compared with placebo (-13.5 m; 90% confidence interval [CI], -38.5 to +∞). At the 3-month follow-up, VM202 improved the maximum treadmill walking time (+2.38 minutes; 90% CI, +1.08 to +∞; P = .014) and increased central nuclei abundance in gastrocnemius muscle (+5.86; 90% CI, +0.37 to +∞; P = .088), compared with placebo. VM202 did not significantly improve pain-free walking distance (difference, +0.30 minutes; 90% CI, -1.10 to +∞; P = .39), calf muscle perfusion (difference, +1.80 mL/min per 100 g tissue; 90% CI, -3.80 to +∞; P = .33), or the Walking Impairment Questionnaire distance score (difference, +2.02; 90% CI, -8.11 to +∞; P = .40). In post hoc analyses, VM202 significantly improved 6-minute walk in PAD participants with diabetes mellitus at 6-month follow-up (+34.19; 90% CI, 4.04 to +∞; P = .075), but had no effect in people without diabetes (interaction P = .079). CONCLUSIONS: These data do not support gastrocnemius injections of VM202 to improve 6-minute walk in PAD. Secondary outcomes suggested potential benefit of VM202 on skeletal muscle measures and treadmill walking, whereas post hoc analyses suggested benefit in PAD participants with diabetes.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. McDermott MM, Sufit R, Domanchuk KJ, et al. Hepatocyte growth factor for walking performance in peripheral artery disease. J Vasc Surg. 2025. PMID: 39778757. doi:10.1016/j.jvs.2024.12.124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。